Skip to main content
APTN
OTC Life Sciences

Adaptin Bio Q3: Cash Falls to $430K, Going Concern Doubt, Pay Deferred

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$6.27
Mkt Cap
$57.895M
52W Low
$5.6
52W High
$6.27
52W Position info
12% above low
Off High info
at 52W high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

APTN is trading near its 52-week low of $5.6 (12% above the low).

Summary

Adaptin Bio's Q3 10-Q shows $430,333 of cash, a going concern warning, and rising unpaid officer and director compensation, with the last batch of in-the-money A Warrants having expired September 30.


Key Events · Earnings and Guidance · APTN

  • Going Concern Doubt Reiterated

    Management states substantial doubt about the ability to continue as a going concern for the next twelve months, with cash of $430,333 against current liabilities of $2,761,098 and an accumulated deficit of $12,600,550.

  • Compensation Being Deferred

    Accrued related-party compensation rose to $621,525 from $54,325 and accrued directors' fees to $105,000 from $26,250, a $567,200 increase in accrued compensation as the company conserves cash.

  • Warrant Exercise Cash Taps Closing

    Nine-month warrant exercises brought in $1,589,514 gross on 361,251 A Warrant shares and $39,999 on 12,121 Exchange Warrant shares, but the remaining 1,039,091 unexercised A Warrants expired September 30, 2026.

  • Loss Narrows on R&D Cuts

    Nine-month net loss was $3,308,749 versus $3,799,551 a year earlier, as R&D fell 64% to $419,700 while G&A held flat at $2,879,444.


Analysis · APTN · Life Sciences

Adaptin Bio closed September with $430,333 of cash against $2.76 million of current liabilities and a $12.6 million accumulated deficit, and management states substantial doubt exists about continuing as a going concern for the next twelve months. To keep the lights on, the company is not paying its people: accrued related-party compensation jumped to $621,525 from $54,325 and accrued directors' fees to $105,000 from $26,250, while accounts payable sits at $1,688,926. The only real cash inflow is warrant exercises, which brought in $1,470,415 net in the nine months, and the remaining 1,039,091 A Warrants expired on September 30, 2026, closing that tap. With the Phase 1 trial of APTN-101 now enrolling and R&D spending cut 64% to $419,700 for the nine months, another equity raise is the likely path, and it would come at the expense of current holders.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, APTN was trading at $6.27 on OTC in the Life Sciences sector, with a market capitalization of approximately $57.9M. The 52-week trading range was $5.60 to $6.27. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

APTN - Latest Insights

APTN
Aug 28, 2026, 4:06 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $6.27
Real-time Price: $6.27 info
Change: $0 (0%) info
Market Cap: $57.895M info
APTN
Aug 20, 2026, 4:02 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $6.27
Real-time Price: $6.27 info
Change: $0 (0%) info
Market Cap: $57.895M info
APTN
Aug 13, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $6.27
Real-time Price: $6.27 info
Change: $0 (0%) info
Market Cap: $57.895M info
APTN
May 18, 2026, 4:30 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $5.60
Real-time Price: $6.27 info
Change: +$0.670 (+12%) info
Market Cap: $57.895M info
APTN
May 15, 2026, 9:01 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $5.60
Real-time Price: $6.27 info
Change: +$0.670 (+12%) info
Market Cap: $57.895M info